1
|
Using AAV vectors expressing the β2-adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size. Sci Rep 2016; 6:23042. [PMID: 26972746 PMCID: PMC4789796 DOI: 10.1038/srep23042] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 02/25/2016] [Indexed: 01/06/2023] Open
Abstract
Anabolic β2-adrenoceptor (β2-AR) agonists have been proposed as therapeutics for treating muscle wasting but concerns regarding possible off-target effects have hampered their use. We investigated whether β2-AR-mediated signalling could be modulated in skeletal muscle via gene delivery to the target tissue, thereby avoiding the risks of β2-AR agonists. In mice, intramuscular administration of a recombinant adeno-associated virus-based vector (rAAV vector) expressing the β2-AR increased muscle mass by >20% within 4 weeks. This hypertrophic response was comparable to that of 4 weeks’ treatment with the β2-AR agonist formoterol, and was not ablated by mTOR inhibition. Increasing expression of inhibitory (Gαi2) and stimulatory (GαsL) G-protein subunits produced minor atrophic and hypertrophic changes in muscle mass, respectively. Furthermore, Gαi2 over-expression prevented AAV:β2-AR mediated hypertrophy. Introduction of the non-muscle Gαs isoform, GαsXL elicited hypertrophy comparable to that achieved by AAV:β2-AR. Moreover, GαsXL gene delivery was found to be capable of inducing hypertrophy in the muscles of mice lacking functional β1- and β2-ARs. These findings demonstrate that gene therapy-based interventions targeting the β2-AR pathway can promote skeletal muscle hypertrophy independent of ligand administration, and highlight novel methods for potentially modulating muscle mass in settings of disease.
Collapse
|
2
|
Mayne RJ, van der Poel C, Woods MG, Lynch GS. Skeletal effects of the alteration of masseter muscle function. AUSTRALASIAN ORTHODONTIC JOURNAL 2015. [DOI: 10.21307/aoj-2020-154] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Abstract
Aim
To investigate the effects of muscle denervation and the introduction of the β2-adrenoceptor agonist, formoterol, on the relationship between muscles and underlying skeletal growth.
Method
Thirty-one (4-week-old) male Sprague-Dawley rats were assigned to four groups: Surgical Sham; Denervated; Denervated +β2-agonist; and β2-agonist only. The Surgical Sham group had the left masseteric nerve exposed but not sectioned. Both of the denervated groups had the left masseteric nerve exposed and sectioned. The groups receiving the β2-agonist had formoterol directly injected into the left masseter muscle every three days for eight weeks. Sixteen angular and linear skeletal measurements were assessed in the overall craniofacial region and the mandible via standardised digital radiography in three views: lateral head, submento-vertex and right and left disarticulated hemi-mandibles.
Results
The findings indicated that, following surgical denervation of the masseter muscle, there were significant changes in the muscle and in the subsequent development of the underlying skeletal structures. The post-surgical changes were largely offset by the administration of a β2-agonist, formoterol, which attenuated muscle atrophy. However, the administration of the β2-agonist only, without surgical denervation, did not lead to changes in skeletal facial form.
Conclusions
Denervation atrophy of the masseter muscle results in statistically significant changes in the development of the underlying skeleton. The changes, however, are localised to areas of muscle attachment. The administration of the β2-agonist, formoterol, despite its effect on muscle anabolism, does not have a significant effect on underlying skeletal growth.
Collapse
Affiliation(s)
- Robert J. Mayne
- * Orthodontic Unit , University of Melbourne , Melbourne , Australia
| | - Chris van der Poel
- † Department of Physiology , University of Melbourne , Melbourne , Australia
| | - Michael G. Woods
- + Oral and Maxillofacial Surgery Unit , Melbourne Health and Royal Melbourne Hospital , Melbourne , Australia
| | - Gordon S. Lynch
- † Department of Physiology , University of Melbourne , Melbourne , Australia
| |
Collapse
|
3
|
Jacobson GA, Yee KC, Premilovac D, Rattigan S. Enantioselective disposition of (R/S)-albuterol in skeletal and cardiac muscle. Drug Test Anal 2013; 6:563-7. [PMID: 24574331 DOI: 10.1002/dta.1575] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 08/13/2013] [Accepted: 09/27/2013] [Indexed: 12/12/2022]
Abstract
Significant enhancement of skeletal muscle function has been observed with racemic albuterol (salbutamol). There is now general acceptance that the R-albuterol enantiomer elicits the pharmacological response, both in the lungs and extrapulmonary, while S-albuterol is pharmacologically inert. The objective of this study was to investigate the distribution of (R/S)-albuterol enantiomers into skeletal and cardiac muscle. Initially oral dosing was undertaken in neonatal mice administered a maximum tolerable dose of racemic albuterol. An in vivo infusion rat model was employed for the investigation of albuterol uptake into skeletal and cardiac muscle over 4 h. Tissue concentrations were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). From the oral dosing model, mean (±SD) levels of racemic albuterol after 5 days were 915 (±293) ng/mL in plasma, 2574 (±196) ng/g in muscle, and 53 (±6.6) ng/g in brain with enantioselective partitioning (muscle:plasma ratio of 5.7 and 1.7 for R- and S-albuterol, respectively). In the infusion model, enantioselective disposition was observed in skeletal muscle (muscle:plasma ratio of 1.2-1.7 and 0.6-0.7 for R- and S-albuterol, respectively) and in cardiac muscle (4.1 and 0.5, respectively). In conclusion, there is greater partitioning of active (R)-albuterol than inactive (S)-albuterol into both skeletal and cardiac muscle compared to plasma. These findings have relevance for albuterol sports doping, cardiac effects, and therapeutic use in muscle wasting diseases. Furthermore, the greater muscle partitioning of the active R-albuterol, and the availability of pure R-albuterol formulations highlight shortcomings in doping control measures using non-enantioselective assays.
Collapse
|
4
|
Thevis M, Thomas A, Beuck S, Butch A, Dvorak J, Schänzer W. Does the analysis of the enantiomeric composition of clenbuterol in human urine enable the differentiation of illicit clenbuterol administration from food contamination in sports drug testing? RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2013; 27:507-512. [PMID: 23322656 DOI: 10.1002/rcm.6485] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2012] [Revised: 11/30/2012] [Accepted: 12/04/2012] [Indexed: 06/01/2023]
Abstract
RATIONALE Clenbuterol (4-amino-α-[(tert-butylamino)methyl]-3,5-dichlorobenzyl alcohol) is approved for human and veterinary use primarily for the treatment of pulmonary afflictions. Despite the authorized administration in cases of medical indications, the misuse of clenbuterol in animal husbandry as well as elite and amateur sport has frequently been reported, arguably due to growth-promoting properties. Due to various recent incidences of doping control specimens containing clenbuterol, strategies towards the discrimination of a surreptitious application from unintended intake via animal-derived edibles or dietary supplements were required. METHODS The enantiomeric compositions of clenbuterol in human urine samples derived from administration studies with therapeutic amounts of the β(2)-agonist and authentic doping control specimens were determined. Due to the facts that therapeutic clenbuterol consists of a racemic mixture of (+)- and (-)-stereoisomers and that the first mentioned (dextrorotatory) stereoisomer is retained to a greater extent in edible animal tissue, the differentiation of a recent administration of therapeutic (and thus racemic) clenbuterol from food contamination (stereoisomerically depleted clenbuterol) was considered. Employing deuterated clenbuterol as internal standard, the target analytes were extracted from human urine by means of concerted liquid-liquid and solid-phase extractions and subjected to chiral liquid chromatography hyphenated to high resolution/high accuracy mass spectrometry with electrospray ionization. RESULTS Both enantiomers of clenbuterol were baseline separated and relative abundances of corresponding labeled and unlabeled stereoisomers were determined, demonstrating that the therapeutic use of clenbuterol results in racemic mixtures in urine for at least 24 h while adverse analytical findings presumably originating from food contaminations can yield (-)-clenbuterol-depleted pairs of analytes. CONCLUSIONS The determination of relative abundances of clenbuterol enantiomers can indicate the ingestion of clenbuterol via contaminated food; however, depletion of (-)-clenbuterol in edible animal tissue is time-dependent and thus results can still be inconclusive as to the inadvertent ingestion of clenbuterol when clenbuterol administration to animals was conducted until slaughter.
Collapse
Affiliation(s)
- Mario Thevis
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
| | | | | | | | | | | |
Collapse
|
5
|
Brooks BR, Juhasz-Poscine K, Waclawik A, Sanjak M, Belden D, Roelke K, Parnell J, Weasler C. Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists. ACTA ACUST UNITED AC 2009. [DOI: 10.1080/14660820050515700] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
6
|
Caruso JF, McLagan JR, Olson NM, Shepherd CM, Taylor ST, Emel TJ. beta(2)-Adrenergic agonist administration and strength training. PHYSICIAN SPORTSMED 2009; 37:66-73. [PMID: 20048511 DOI: 10.3810/psm.2009.06.1711] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
beta(2)-Adrenergic agonists (beta(2)AA) produce myriad effects throughout the human body. Prescribed concurrently with theophylline for the bronchodilatory effects they offer in the treatment of asthma and chronic obstructive pulmonary disease, beta(2)AA actions include many beneficial and adverse changes when administered to animals at supraphysiological doses. Beneficial changes include improved musculoskeletal health and function, which can be maintained because adverse changes are reduced if oral beta(2)AA are given at therapeutic dosages in humans with concurrent resistive exercise administration. Combined oral beta(2)AA-resistive exercise treatments have been shown to produce gains in musculoskeletal health and function in numerous healthy and disuse atrophy human models. The mechanism(s) by which beta(2)AA exert their effects are a function of multiple factors, not the least of which includes the type of model receiving the drug treatment. Combined oral beta(2)AA-resistive exercise treatments in humans showed that adverse effects were greatly reduced when prudent and safer drug administration practices were employed (eg, screening subjects for tolerance before drug treatment). Results from human research trials suggest that administration of the combined treatment improves musculoskeletal function and performance with minimal health risk if proper precautions are followed. A related issue is administration of the combined treatment as an ergogenic aid to athletic performance. Given the results presented in this article, physicians should be wary of potential drug abuse and administer beta(2)AA only under appropriate circumstances when such a treatment is warranted.
Collapse
Affiliation(s)
- John F Caruso
- Exercise and Sports Science Program, 312 Chapman Hall, 600 S. College Avenue, University of Tulsa, Tulsa, OK 74104, USA.
| | | | | | | | | | | |
Collapse
|
7
|
Soić-Vranić T, Bobinac D, Bajek S, Jerković R, Malnar-Dragojević D, Nikolić M. Effect of salbutamol on innervated and denervated rat soleus muscle. Braz J Med Biol Res 2005; 38:1799-805. [PMID: 16302094 DOI: 10.1590/s0100-879x2005001200008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The objective of the present investigation was to perform a 14-day time-course study of treatment with salbutamol, a beta2 adrenoceptor agonist, on rat soleus muscle in order to assess fiber type selectivity in the hypertrophic response and fiber type composition. Male Wistar rats were divided into four groups: control (N = 10), treated with salbutamol (N = 30), denervated (N = 30), and treated with salbutamol after denervation (N = 30). Salbutamol was injected intraperitoneally in the rats of the 2nd and 4th groups at a concentration of 0.3 mg/kg twice a day for 2 weeks. The muscles were denervated using the crush method with pean. The animals were sacrificed 3, 6, 9, 12, and 14 days after treatment. Frozen cross-sections of soleus muscle were stained for myosin ATPase, pH 9.4. Cross-sectional area and percent of muscle fibers were analyzed morphometrically by computerized image analysis. Treatment with salbutamol induced hypertrophy of all fiber types and a higher percentage of type II fibers (21%) in the healthy rat soleus muscle. Denervation caused marked atrophy of all fibers and conversion from type I to type II muscle fibers. Denervated muscles treated with salbutamol showed a significantly larger cross-sectional area of type I muscle fibers, 28.2% compared to the denervated untreated muscle. Moreover, the number of type I fibers was increased. These results indicate that administration of salbutamol is able to induce changes in cross-sectional area and fiber type distribution in the early phase of treatment. Since denervation-induced atrophy and conversion from type I to type II fibers were improved by salbutamol treatment we propose that salbutamol, like other beta2 adrenoceptor agonists, may have a therapeutic potential in improving the condition of skeletal muscle after denervation.
Collapse
Affiliation(s)
- T Soić-Vranić
- Department of Anatomy, Medical Faculty, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia.
| | | | | | | | | | | |
Collapse
|
8
|
Thevis M, Schebalkin T, Thomas A, Schänzer W. Quantification of Clenbuterol in Human Plasma and Urine by Liquid Chromatography-Tandem Mass Spectrometry. Chromatographia 2005. [DOI: 10.1365/s10337-005-0651-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
9
|
Hinkle RT, Donnelly E, Cody DB, Sheldon RJ, Isfort RJ. Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force. J Appl Physiol (1985) 2005; 98:655-62. [PMID: 15649881 DOI: 10.1152/japplphysiol.00736.2004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Of the two known vasoactive intestinal peptide receptors (VPAC1R and VPAC2R), the VPAC2R is expressed in skeletal muscle. To evaluate the function of the VPAC2R in the physiological control of skeletal muscle mass, we utilized the VPAC1R selective agonist [K15,R16,L27]VIP(1-7) GRF(8-27)-NH2 and the VPAC2R selective agonist Ro-25-1553 to treat mice and rats undergoing either nerve damage-, corticosteroid-, or disuse-induced skeletal muscle atrophy. These analyses demonstrated that activation of VPAC2R, but not VPAC1R, reduced the loss of skeletal muscle mass and force during conditions of skeletal muscle atrophy resulting from corticosteroid administration, denervation, casting-induced disuse, increased skeletal muscle mass, and force of nonatrophying muscles. These studies indicate that VPAC2R agonists may have utility for the treatment of skeletal muscle-wasting diseases.
Collapse
Affiliation(s)
- Richard T Hinkle
- Research Division, Procter & Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd., Mason, OH 45040-9317, USA
| | | | | | | | | |
Collapse
|
10
|
Busquets S, Figueras MT, Fuster G, Almendro V, Moore-Carrasco R, Ametller E, Argilés JM, López-Soriano FJ. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004; 64:6725-31. [PMID: 15374990 DOI: 10.1158/0008-5472.can-04-0425] [Citation(s) in RCA: 129] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
In cancer cachexia both cardiac and skeletal muscle suffer an important protein mobilization as a result of increased proteolysis. Administration of the beta2-agonist formoterol to both rats and mice bearing highly cachectic tumors resulted in an important reversal of the muscle-wasting process. The anti-wasting effects of the drug were based on both an activation of the rate of protein synthesis and an inhibition of the rate of muscle proteolysis. Northern blot analysis revealed that formoterol treatment resulted in a decrease in the mRNA content of ubiquitin and proteasome subunits in gastrocnemius muscles; this, together with the decreased proteasome activity observed, suggest that the main anti-proteolytic action of the drug may be based on an inhibition of the ATP-ubiquitin-dependent proteolytic system. Interestingly, the beta2-agonist was also able to diminish the increased rate of muscle apoptosis (measured as DNA laddering as well as caspase-3 activity) present in tumor-bearing animals. The present results indicate that formoterol exerted a selective, powerful protective action on heart and skeletal muscle by antagonizing the enhanced protein degradation that characterizes cancer cachexia, and it could be revealed as a potential therapeutic tool in pathologic states wherein muscle protein hypercatabolism is a critical feature such as cancer cachexia or other wasting diseases.
Collapse
MESH Headings
- Adrenergic beta-Agonists/pharmacology
- Animals
- Cachexia/drug therapy
- Cachexia/metabolism
- Cachexia/pathology
- Carcinoma, Lewis Lung/metabolism
- Carcinoma, Lewis Lung/pathology
- Disease Models, Animal
- Eating/drug effects
- Ethanolamines/pharmacology
- Formoterol Fumarate
- Liver Neoplasms, Experimental/metabolism
- Liver Neoplasms, Experimental/pathology
- Male
- Mice
- Mice, Inbred C57BL
- Muscle Proteins/metabolism
- Muscle, Skeletal/drug effects
- Muscle, Skeletal/metabolism
- Muscle, Skeletal/pathology
- Neoplasms, Experimental/metabolism
- Neoplasms, Experimental/pathology
- Rats
- Rats, Wistar
- Sarcoma, Yoshida/metabolism
- Sarcoma, Yoshida/pathology
Collapse
Affiliation(s)
- Sílvia Busquets
- Cancer Research Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Agrawal S, Thakur P, Katoch SS. Beta Adrenoceptor Agonists, Clenbuterol, and Isoproterenol Retard Denervation Atrophy in Rat Gastrocnemius Muscle: Use of 3-Methylhistidine as a Marker of Myofibrillar Degeneration. ACTA ACUST UNITED AC 2003; 53:229-37. [PMID: 14529584 DOI: 10.2170/jjphysiol.53.229] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The effects of beta adrenergic agonists, clenbuterol (2 mg/kg body weight/d) and isoproterenol (12 mg/kg body weight/d), in normal innervated and denervated rat gastrocnemius muscle were investigated. The daily administration of beta adrenergic agonists to normal innervated rats for a short period (7 d) resulted in the hypertrophy of gastrocnemius as confirmed from the measurement of total tissue protein contents. The development of denervation atrophy witnessed a stimulation in the expression of acid and alkaline phosphatases, pointing to an enhanced myofibrillar degeneration. An administration of beta adrenergic agonists inhibited the expression of raised levels of these enzymes in denervated muscle. A measurement of 3-methylhistidine in muscle revealed a loss of amino acid with the progress in the development of denervation atrophy. Serum and urine samples from denervated rats showed a progressive accumulation of 3-methylhistidine. Clenbuterol and isoproterenol treatment to these rats resulted in an inhibition of 3-methylhistidine accumulation. When 3-methylhistidine was used as a marker of myofibrillar degeneration, the results seemed to suggest that the degeneration of cyto-contractile apparatus accompanying denervation atrophy is attenuated in the presence of beta adrenergic agonists, implying that these sympathomimetic drugs are capable of reversing denervation atrophy in rat gastrocnemius.
Collapse
Affiliation(s)
- Sapna Agrawal
- Department of Biosciences, Himachal Pradesh University, Summer Hill, Shimla-171 005, India
| | | | | |
Collapse
|
12
|
Cockman MD, Jones MB, Prenger MC, Sheldon RJ. Magnetic resonance imaging of denervation-induced muscle atrophy: effects of clenbuterol in the rat. Muscle Nerve 2001; 24:1647-58. [PMID: 11745974 DOI: 10.1002/mus.1200] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
We show that magnetic resonance imaging (MRI) can be used to quantify the amount of muscle in the lower legs of adult rats and to noninvasively monitor the onset and progression of denervation-induced atrophy. Muscle cross-sectional areas determined from 2D gradient-echo MR images allow longitudinal quantification of the protective effects of a beta(2)-adrenergic agonist clenbuterol. We also show that the estimation of clenbuterol's efficacy is improved by computation of the muscle volume. Rapid animal throughput and the ability to accurately estimate efficacy make MRI an attractive technology for studying skeletal muscle atrophy and hypertrophy, allowing the evaluation of potential therapies in longitudinal studies.
Collapse
Affiliation(s)
- M D Cockman
- Procter and Gamble Pharmaceuticals, Health Care Research Center, DS1-2E7, Box 1052, 8700 Mason-Montgomery Road, Mason, Ohio 45040, USA.
| | | | | | | |
Collapse
|
13
|
Frerichs O, Fansa H, Ziems P, Schneider W, Keilhoff G. Regeneration of peripheral nerves after clenbuterol treatment in a rat model. Muscle Nerve 2001; 24:1687-91. [PMID: 11745978 DOI: 10.1002/mus.10006] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Clenbuterol is known to act as a neuroprotective substance in the central nervous system, and also reduces muscle atrophy after denervation. The aim of this study was to evaluate its influence on peripheral nerve regeneration. The rat sciatic nerve model was used in four groups (n = 8 per group). After complete nerve transection and microsurgical coaptation, two groups received a daily oral dose of 100 microg/kg clenbuterol and two served as controls. Regeneration was assessed clinically, histologically, and morphometrically after 4 and 6 weeks. The weight ratios of calf muscles were calculated. Histological examination showed significantly increased axon counts in the clenbuterol group and a better degree of myelination. Muscle weight ratios of the clenbuterol group were significantly increased after 6 weeks, and the animals showed improved function of the hindlimb. Thus, therapy with 100 microg/kg clenbuterol daily after coaptation of a sciatic nerve showed a positive influence on clinical, histological, and morphometrical parameters in the rat model. The underlying mechanism remains unclear.
Collapse
Affiliation(s)
- O Frerichs
- Department of Plastic, Reconstructive, and Hand Surgery, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany.
| | | | | | | | | |
Collapse
|
14
|
von Deutsch DA, Abukhalaf IK, Wineski LE, Aboul-Enein HY, Pitts SA, Parks BA, Oster RA, Paulsen DF, Potter DE. Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers. Chirality 2000; 12:637-48. [PMID: 10897101 DOI: 10.1002/1520-636x(2000)12:8<637::aid-chir6>3.0.co;2-w] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Clenbuterol is a relatively selective beta2-adrenergic partial agonist that has bronchodilator activity. This drug has been investigated as a potential countermeasure to microgravity- or disuse-induced skeletal muscle atrophy because of presumed anabolic effects. The purpose of this study was to: 1) analyze the anabolic effect of clenbuterol's (-)-R and (+)-S enantiomers (0.2 mg/kg) on muscles (cardiac and skeletal) and other organs; and 2) compare responses of enantiomers to the racemate (0.4 mg/kg and 1.0 mg/kg). Male Sprague Dawley rats were treated with: a) racemic clenbuterol (rac-clenbuterol, 0.4 or 1.0 mg/kg); b) enantiomers [clenbuterol (-)-R or (+)-S]; or c) vehicle (1.0 mL/kg buffered saline). Anabolic activity was determined by measuring tissue mass and protein content. HPLC teicoplanin chiral stationary phase was used to directly resolve racemic clenbuterol to its individual enantiomers. In skeletal muscle, both enantiomers had equal anabolic activity, and the effects were muscle- and anatomic region-specific in magnitude. Although the enantiomers did not affect the ventricular mass to body weight ratio, clenbuterol (+)-S induced a small but significant increase in ventricular mass. Both clenbuterol enantiomers produced significant increases in skeletal muscle mass, while being less active in producing cardiac ventricular muscle hypertrophy than the racemic mixture.
Collapse
Affiliation(s)
- D A von Deutsch
- Musculoskeletal Research Group, Space Medicine and Life Sciences Research Center, Morehouse School of Medicine, Atlanta, Georgia 30310-1495, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Sneddon AA, Delday MI, Maltin CA. Amelioration of denervation-induced atrophy by clenbuterol is associated with increased PKC-alpha activity. Am J Physiol Endocrinol Metab 2000; 279:E188-95. [PMID: 10893339 DOI: 10.1152/ajpendo.2000.279.1.e188] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Rat soleus muscle was denervated for 3 or 7 days, and total membrane protein kinase C (PKC) activity and translocation and immunocytochemical localization of PKC isoforms were examined. Dietary administration of clenbuterol concomitant with denervation ameliorated the atrophic response and was associated with increased membrane PKC activity at both 3 (140%) and 7 (190%) days. Of the five PKC isoforms (alpha, epsilon, theta, zeta, and mu) detected in soleus muscle by Western immunoblotting, clenbuterol treatment affected only the PKC-alpha and PKC-theta forms. PKC-alpha was translocated to the membrane fraction upon denervation, and the presence of clenbuterol increased membrane-bound PKC-alpha and active PKC-alpha as assayed by Ser(657) phosphorylation. PKC-theta protein was downregulated upon denervation, and treatment with clenbuterol further decreased both cytosolic and membrane levels. Immunolocalization of PKC-theta showed differences for regulatory and catalytic domains, with the latter showing fast-fiber type specificity. The results suggest potential roles of PKC-alpha and PKC-theta in the mechanism of action of clenbuterol in alleviating denervation-induced atrophy.
Collapse
Affiliation(s)
- A A Sneddon
- The Rowett Research Institute, Bucksburn, Aberdeen, Scotland AB21 9SB.
| | | | | |
Collapse
|
16
|
Abukhalaf IK, von Deutsch DA, Parks BA, Wineski L, Paulsen D, Aboul-Enein HY, Potter DE. Comparative analytical quantitation of clenbuterol in biological matrices using GC-MS and EIA. Biomed Chromatogr 2000; 14:99-105. [PMID: 10694703 DOI: 10.1002/(sici)1099-0801(200004)14:2<99::aid-bmc933>3.0.co;2-g] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A simple and sensitive procedure utilizing GC-MS for the identification and quantitation of clenbuterol in biofluids and tissues is described. This improved method utilizes trimethylboroxine for the derivatization of clenbuterol, requires only 1 mL/g of biological sample, and most importantly does not require an extra cleaning step for urine specimens prior to extraction. Linear quantitative response curves have been generated for derivatized clenbuterol over a concentration range of 5-200 ng/mL. The extraction efficiency at four representative points of the standard curve exceeded 90% in both specimen types (plasma and urine). Linear regression analyses of the standard curve in both specimen types exhibited correlation coefficients ranging from 0.997 to 1.000. The Limit of detection (LOD) and Limit of quantitation (LOQ) values for plasma specimens were determined to be 0.5 and 1.5 ng/mL respectively. For urine specimens, LOD and LOQ values were 0.2 and 0.7 ng/microL respectively. Percentage recoveries ranged from 91 to 95% for urine and 89 to 101% for plasma. Precision and accuracy (within-run and between-run) studies reflected a high level of reliability and reproducibility of the method. In addition to its reliability, sensitivity and simplicity, this modified procedure is more efficient and cost effective, requiring less time, only 1 mL of sample, and minimal amounts of extraction solvents. The applicability of the method for the detection and quantitation of clenbuterol in biological tissues of rats treated with the drug was demonstrated successfully. For comparative analysis of clenbuterol in plasma and liver samples, both GC-MS and enzyme immunoassay (EIA) methods are found to be suitable. Due to potential antibody-cross reactivity with EIA, the GC-MS method is the method of choice for most samples because of its specificity. However, the EIA method is considered the method of choice for analysis of clenbuterol found in concentrations below the limits of quantitation by GC-MS due to its sensitivity.
Collapse
Affiliation(s)
- I K Abukhalaf
- Department of Pharmacology and Toxicology, Morehouse School of Medicine, Atlanta, GA 30310, USA
| | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
Evidence of dystrophic muscle degeneration in the hind limb muscles of young (20-week-old) treadmill-exercised or aged (87-week-old) sedentary mdx mice was greatly reduced by treatment with clenbuterol, a beta(2)-adrenoceptor agonist. Daily treadmill exercise for 10 weeks increased the size of regions within the mdx plantaris but not the soleus or gastrocnemius muscles, in which necrotic muscle fibers or the absence of fibers was observed. Clenbuterol reduced the size of these abnormal regions from 21% of total muscle cross-sectional area to levels (4%) found in sedentary mdx mice. In addition, the muscles obtained from aged clenbuterol-treated mdx or wild-type mice did not display the extensive fibrosis or fiber loss observed in untreated mdx mice. These observations are consistent with a mechanism of dystrophic muscle degeneration caused by work load-induced injury that is cumulative with aging and is opposed by beta(2)-adrenoceptor activation. Optimization of beta(2)-agonist treatment of muscular dystrophy in mdx mice may lead to a useful therapeutic modality for human forms of the disease.
Collapse
MESH Headings
- Adrenergic beta-Agonists/pharmacology
- Aging/physiology
- Animals
- Clenbuterol/pharmacology
- Humans
- Mice
- Mice, Inbred C57BL
- Mice, Inbred mdx
- Muscle Development
- Muscle, Skeletal/drug effects
- Muscle, Skeletal/growth & development
- Muscle, Skeletal/pathology
- Muscle, Skeletal/physiopathology
- Muscular Dystrophy, Animal/pathology
- Muscular Dystrophy, Animal/physiopathology
- Muscular Dystrophy, Animal/prevention & control
- Physical Conditioning, Animal/physiology
- Physical Exertion/drug effects
- Physical Exertion/physiology
Collapse
Affiliation(s)
- R J Zeman
- Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USA.
| | | | | | | |
Collapse
|
18
|
Petrou M, Clarke S, Morrison K, Bowles C, Dunn M, Yacoub M. Clenbuterol increases stroke power and contractile speed of skeletal muscle for cardiac assist. Circulation 1999; 99:713-20. [PMID: 9950671 DOI: 10.1161/01.cir.99.5.713] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Skeletal muscle assist (SMA) may be limited by loss of power, slowing of contraction and relaxation, and atrophy of the transformed latissimus dorsi muscle (LD). Clenbuterol (clen), a beta2-adrenergic receptor agonist, was used to improve the performance of trained skeletal muscle in sheep. METHODS AND RESULTS The following 4 groups were used: A (n=6), untrained controls; B (n=6), left LD progressively transformed toward a slow-twitch and fatigue-resistant phenotype by electrical stimulation over 12 weeks (2.5 to 5 V, 240- microsec pulse duration, 35 Hz, 3 to 6 pulses per burst, and up to 40 bursts per minute); C (n=6), clen-treated (0.5 mg/kg SC) for 12 weeks; and D (n=6), clen+trained. In a terminal experiment, the mobilized LD was wrapped around a rubber aorta of a mock circulation and stimulated to contract 40 times per minute. Group A had an initial mean pressure augmentation (DeltaP) of 24.6 mm Hg and stroke power of 2.28 W/kg, but both fell to <20% of their original values by 15 minutes because of fatigue (P<0.005). Group B was fatigue-resistant, with a DeltaP and stroke power at 60 minutes of 13 mm Hg (70% of initial) and 0.34 W/kg (39% of initial), respectively. The performance of group C was similar to that of controls. In group D, however, the muscles were stronger at all time points than in B, with a DeltaP of 23 mm Hg and stroke power of 2.66 W/kg at 60 minutes (P<0.01). The speeds of contraction (+dP/dt:DeltaP) and relaxation (-dP/dt:DeltaP) were significantly greater in group D than B. Protein analyses showed group D to have only a trend toward greater abundance of the fast isoforms of myosin heavy chain and sarcoplasmic reticulum Ca2+-ATPase (P>0.1). CONCLUSIOINS: ++Clen improves the performance of trained skeletal muscle in a model of aortomyoplasty by unknown mechanisms. These findings may have important implications in SMA.
Collapse
Affiliation(s)
- M Petrou
- Imperial College, National Heart and Lung Institute, London, UK
| | | | | | | | | | | |
Collapse
|
19
|
Carbó N, López-Soriano J, Tarragó T, González O, Llovera M, López-Soriano FJ, Argilés JM. Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett 1997; 115:113-8. [PMID: 9097986 DOI: 10.1016/s0304-3835(97)04718-6] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The implantation of the Yoshida AH-130 ascites hepatoma (a fast growing tumour) to rats resulted in a dramatic loss of both white adipose tissue and muscle (skeletal and cardiac) mass. Administration of beta2-adrenergic agonists to tumour-bearing rats resulted in a partial recovery of skeletal muscle and heart mass. Treatment of the tumour-bearing animals with the different drugs (salbutamol, salmeterol and clenbuterol) did not influence tumour growth or food intake so it can be suggested that the effects were solely due to metabolic changes. In addition, while the three drugs had clear effects on gastrocnemius muscles, clenbuterol and salbutamol had also an effect on soleus, and salbutamol had a clear effect on cardiac muscle. It is suggested that any of the studied beta2-adrenergic agonists (but perhaps, particularly salmeterol) could be used clinically in the treatment of cancer cachexia.
Collapse
Affiliation(s)
- N Carbó
- Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
20
|
Haycock JW, Falkous G, Maltin CA, Delday MI, Mantle D. Effect of prednisone on protease activities and structural protein levels in rat muscles in vivo. Clin Chim Acta 1996; 249:47-58. [PMID: 8737591 DOI: 10.1016/0009-8981(95)06257-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
To further elucidate the biochemical mechanism by which the corticosteroid prednisone induces differential changes in muscle mass (via altered protein synthesis/degradation rates) in normal or degenerating muscle tissues, we have determined the activity of a range of proteolytic enzyme types, together with levels of muscle structural proteins, in five innervated and denervated muscle types from control and drug treated rats. In both normal and wasting muscles, the activity of many protease types was substantially down-regulated following treatment with prednisone; however, accompanying net decreases in muscle mass were observed (although the structural protein composition of muscles was unaltered following drug treatment). We conclude that whilst overall rates of protein degradation in both normal and degenerating muscle may be reduced (via protease down-regulation) following prednisone treatment, the effect of the latter in reducing protein synthesis rates must be proportionately greater (even in actively degenerating tissue). Thus, the data do not support the hypothesis that the beneficial effect of prednisone in maintaining muscle mass in pathological tissues (e.g., Duchenne muscular dystrophy (DMD)) operates principally via down-regulation of protease action/protein catabolism.
Collapse
Affiliation(s)
- J W Haycock
- Muscular Dystrophy Group Research Laboratories, Newcastle General Hospital, Newcastle upon Tyne, UK
| | | | | | | | | |
Collapse
|
21
|
Dupont-Versteegden EE, Katz MS, McCarter RJ. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. Muscle Nerve 1995; 18:1447-59. [PMID: 7477069 DOI: 10.1002/mus.880181216] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Long-term administration of the beta 2-adrenergic agonist clenbuterol in mdx mice was used to test the hypothesis that increasing contractile protein content in skeletal muscle will decrease the progression of muscular dystrophy. C57BL/10SNJ (control) and dystrophic (mdx) mice were given clenbuterol (1.0-1.5 mg/kg body weight/day) in the drinking water. Ventilatory function and morphological and functional characteristics of soleus (SOL) and diaphragm (DIA) muscles were evaluated. Clenbuterol administration was associated with increased SOL muscle weight, and SOL muscle weight to body weight ratio in control and mdx mice at both ages. There was a 22% increase in myosin concentration of mdx DIA at 1 year of age, correlating well with increased normalized active tension in mdx DIA at this age. Also, absolute tetanic tension increased in control and mdx SOL with clenbuterol at both ages. Ventilatory function was significantly impaired in mdx mice at both ages and clenbuterol administration did not alleviate this. Clenbuterol treatment was associated with a 30-40% increase in fatigability in DIA and SOL muscles of control and mdx mice at both ages. Furthermore, 1-year-old mdx mice receiving clenbuterol exhibited deformities in hindlimbs and spine. These results suggest that long-term clenbuterol treatment has a positive effect on muscle growth and force generation, but has adverse side effects such as increased muscle fatigability and development of deformities.
Collapse
|
22
|
Petrou M, Wynne DG, Boheler KR, Yacoub MH. Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation 1995; 92:II483-9. [PMID: 7586459 DOI: 10.1161/01.cir.92.9.483] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND Skeletal muscle assistance of the circulation for patients in end-stage heart failure requires electrical training of the latissimus dorsi flap to produce fatigue resistance. This process of electrical transformation and the development of postmobilization atrophy results in a profound loss in peak power generated. The beta 2-adrenoceptor agonist clenbuterol was used to investigate its potential to selectively induce skeletal muscle hypertrophy, particularly the latissimus dorsi muscle (LDM), independent of adverse effects on cardiac muscle. METHODS AND RESULTS Forty-one male Sprague-Dawley rats were divided into four groups and used in this study. Clenbuterol 2 micrograms.g body wt-1.d-1 was administered subcutaneously for a period of either 5 weeks (group A) or 2 weeks (group A1). Groups B and B1 (controls) were injected with 0.5 mL normal saline once daily. At the end of the experimental period, all rats were weighed and terminally anesthetized for removal of the left LDM, left gastrocnemius-plantaris-soleus (GPS) muscles, and heart. The results showed that the increase in body weight did not differ significantly between the clenbuterol-treated and control groups (P > .5). The ratio of LDM to tibial length (hypertrophic index) for groups A and A1 was significantly greater than controls (P < .01), which represented a 20% to 29% increase. The hypertrophy was more pronounced for hindlimb skeletal muscle (21% to 35% for GPS), and the effects of this relatively high dose of clenbuterol on the heart were less marked (18% to 20% hypertrophy). RNA analyses indicate that ventricles of clenbuterol-treated rats express elevated levels of mRNA to atrial natriuretic factor without a concomitant increase in skeletal alpha-actin and beta-myosin heavy chain, consistent with a "physiological" form of cardiac hypertrophy. CONCLUSIONS Clenbuterol induces significant hypertrophy of the LDM associated with specific changes in cardiac gene expression.
Collapse
Affiliation(s)
- M Petrou
- Royal Brompton National Heart and Lung Institute, London, UK
| | | | | | | |
Collapse
|
23
|
Agbenyega ET, Morton RH, Hatton PA, Wareham AC. Effect of the beta 2-adrenergic agonist clenbuterol on the growth of fast- and slow-twitch skeletal muscle of the dystrophic (C57BL6J dy2J/dy2J) mouse. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. PART C, PHARMACOLOGY, TOXICOLOGY & ENDOCRINOLOGY 1995; 111:397-403. [PMID: 8564781 DOI: 10.1016/0742-8413(95)00066-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Clenbuterol (4mg/kg in diet for 21 days) had no statistically significant effect on whole body growth. It did cause a significant increase (18.2%) in wet weight of the fast twitch muscle extensor digitorum longus (EDL) and a corresponding 14.9% increase in total muscle protein. In transverse sections through dystrophic muscle fibre sizes were more variable than in normal muscle. Clenbuterol treatment resulted in a reduction in the proportion of small diameter fibres, and therefore an increase in mean fibre diameter, in dystrophic EDL. Clenbuterol had no significant effect upon the slow twitch muscle soleus.
Collapse
Affiliation(s)
- E T Agbenyega
- Division of Neuroscience, School of Biological Sciences, University of Manchester
| | | | | | | |
Collapse
|
24
|
Costelli P, Llovera M, García-Martínez C, Carbó N, López-Soriano FJ, Argilés JM. Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Lett 1995; 91:73-8. [PMID: 7750097 DOI: 10.1016/0304-3835(94)03719-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The growth of the rat ascites hepatoma Yoshida AH-130 causes marked tissue protein hypercatabolism and alterations of the hormonal homeostasis in the host. After a single intravenous tracer dose of L-[1-14C]leucine in vivo, 14CO2 release by tumour-bearing rats is significantly elevated with respect to the controls. Treatment of the tumour hosts with a beta-adrenergic agonist (clenbuterol) is able to prevent either the depletion of the skeletal muscle mass or the enhanced whole-body leucine oxidation. Incubation of soleus muscles in the presence of L-[1-14C]leucine indicates an increased ability of the muscle obtained from the tumour hosts to utilize the amino acid for oxidation. Similarly to what is observed in vivo, clenbuterol administration exerts a protective effect reducing the rate of leucine oxidation to the control levels.
Collapse
Affiliation(s)
- P Costelli
- Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Italy
| | | | | | | | | | | |
Collapse
|
25
|
Costelli P, García-Martínez C, Llovera M, Carbó N, López-Soriano FJ, Agell N, Tessitore L, Baccino FM, Argilés JM. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 1995; 95:2367-72. [PMID: 7738199 PMCID: PMC295859 DOI: 10.1172/jci117929] [Citation(s) in RCA: 102] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Tissue protein hypercatabolism (TPH) is a most important feature in cancer cachexia, particularly with regard to the skeletal muscle. The rat ascites hepatoma Yoshida AH-130 is a very suitable model system for studying the mechanisms involved in the processes that lead to tissue depletion, since it induces in the host a rapid and progressive muscle waste mainly due to TPH (Tessitore, L., G. Bonelli, and F. M. Baccino. 1987. Biochem. J. 241:153-159). Detectable plasma levels of tumor necrosis factor-alpha associated with marked perturbations in the hormonal homeostasis have been shown to concur in forcing metabolism into a catabolic setting (Tessitore, L., P. Costelli, and F. M. Baccino. 1993. Br. J. Cancer. 67:15-23). The present study was directed to investigate if beta 2-adrenergic agonists, which are known to favor skeletal muscle hypertrophy, could effectively antagonize the enhanced muscle protein breakdown in this cancer cachexia model. One such agent, i.e., clenbuterol, indeed largely prevented skeletal muscle waste in AH-130-bearing rats by restoring protein degradative rates close to control values. This normalization of protein breakdown rates was achieved through a decrease of the hyperactivation of the ATP-ubiquitin-dependent proteolytic pathway, as previously demonstrated in our laboratory (Llovera, M., C. García-Martínez, N. Agell, M. Marzábal, F. J. López-Soriano, and J. M. Argilés. 1994. FEBS (Fed. Eur. Biochem. Soc.) Lett. 338:311-318). By contrast, the drug did not exert any measurable effect on various parenchymal organs, nor did it modify the plasma level of corticosterone and insulin, which were increased and decreased, respectively, in the tumor hosts. The present data give new insights into the mechanisms by which clenbuterol exerts its preventive effect on muscle protein waste and seem to warrant the implementation of experimental protocols involving the use of clenbuterol or alike drugs in the treatment of pathological states involving TPH, particularly in skeletal muscle and heart, such as in the present model of cancer cachexia.
Collapse
Affiliation(s)
- P Costelli
- Departament de Bioquímica i Fisiologia, Facultat de Biologia, Universitat de Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Signorile JF, Banovac K, Gomez M, Flipse D, Caruso JF, Lowensteyn I. Increased muscle strength in paralyzed patients after spinal cord injury: effect of beta-2 adrenergic agonist. Arch Phys Med Rehabil 1995; 76:55-8. [PMID: 7811176 DOI: 10.1016/s0003-9993(95)80043-3] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The administration of beta-2 adrenergic agonists in experimental animals result in an increased strength of skeletal muscle. In this study, we evaluated whether a beta-2 adrenergic agonist, metaproterenol, had an effect on muscle size and strength in a group of patients with muscular atrophy following spinal cord injury. Ten male subjects were randomly divided into 2 groups and agreed to participate in a prospective, double-blind, placebo-controlled, and crossover study. Metaproterenol (80 mg/day), or placebo, was administered orally for a period of 4 weeks. Muscle strength was measured by a force transducer interfaced with a microcomputer. Muscle size was calculated and expressed as a cross-sectional area of upper arm and forearm using a formula. Metaproterenol induced a significant increase of muscle strength in both groups of subjects, compared with placebo (p < .001). Similarly, there was an increase in a muscle size in the forearm following the administration of metaproterenol. Our data indicate that beta-2 adrenergic agonists may improve both muscle strength and size in patients with muscular atrophy following spinal cord paralysis.
Collapse
Affiliation(s)
- J F Signorile
- Department of Exercise and Sport Sciences, School of Medicine, University of Miami, FL 33101
| | | | | | | | | | | |
Collapse
|
27
|
Hayes A, Williams DA. Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice. Clin Exp Pharmacol Physiol 1994; 21:757-65. [PMID: 7867226 DOI: 10.1111/j.1440-1681.1994.tb02443.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
1. This study was designed to establish whether long-term treatment with the powerful anabolic agent clenbuterol has beneficial effects on dystrophin-deficient skeletal muscle function. 2. Normal (C57BL/10) and dystrophic (mdx) mice were administered clenbuterol (2 mg/kg per day) for 15 weeks. At 20 weeks of age, the extensor digitorum longus (EDL) and soleus muscles were removed, and their contractile and histochemical properties analysed. 3. Absolute and relative muscle masses were larger (P < 0.001) in mdx compared to C57BL/10 mice. These larger muscles produced larger absolute forces (P < 0.01) in the soleus of mdx mice compared to normal mice. Relative tetanic force was also larger (P < 0.05) in the soleus of mdx mice. In contrast, the absolute tetanic tension of the EDL was reduced (P < 0.01) in mdx mice compared to C57BL/10 mice, and both relative twitch and tetanic tensions were also lower (P < 0.001) in mdx mice. 4. Clenbuterol increased the lean muscle mass in both normal (10%, P < 0.05 and 20%, P < 0.01 for the EDL and soleus, respectively) and dystrophic (7%, P < 0.05 and 11%, P < 0.01) groups. Twitch contraction times were significantly faster in both the EDL (P < 0.001) and soleus (P < 0.01) muscles following clenbuterol administration, supported by fibre-type transitions towards fast-twitch fibres. Relative force levels of the soleus muscle of both C57BL/10 (40%, P < 0.01) and mdx (20%, P < 0.01) mice were increased significantly following clenbuterol treatment. No changes in the absolute or relative forces of the EDL muscles were observed in response to clenbuterol administration. 5. Clenbuterol was thus able to increase the force output of a slow-twitch, mixed (hence human-like) muscle but not fast-twitch muscle from mdx mice. The results lend tentative support to the potential role of clenbuterol as an anabolic agent in the treatment of muscle wasting diseases.
Collapse
Affiliation(s)
- A Hayes
- Department of Physiology, University of Melbourne, Parkville, Victoria, Australia
| | | |
Collapse
|
28
|
Carter WJ, Lynch ME. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metabolism 1994; 43:1119-25. [PMID: 7916118 DOI: 10.1016/0026-0495(94)90054-x] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Aging decreases skeletal muscle mass and strength, making elderly subjects particularly vulnerable to catabolic effects of age-related diseases. Clenbuterol, a muscle anabolic beta 2-adrenergic agonist, has reduced or restored skeletal muscle losses in experimental catabolic states. However, the doses of clenbuterol used to prevent or reverse muscle wasting in most animal models have exceeded the estimated safe dose in man. Recently, another beta 2-adrenergic agonist, salbuamol (albuterol), has been shown to increase muscle weight and protein content in young rats at a dose similar to that used clinically. In contrast to clenbuterol, salbutamol is currently approved for human use as a bronchodilator in the United States. This study has compared the muscle and protein anabolic effects of salbutamol at a clinically relevant dose with those of clenbuterol at a dose typically used in animal models of muscle wasting. Salbutamol and clenbuterol were administered by implanted osmotic minipumps to Fisher-344 rats aged 3 and 24 months at doses of 1.03 mg and 600 micrograms per kilogram per 24 hours for 3 weeks. The weights of five hindlimb muscles, as well as carcass protein and fat content, were determined. Salbutamol and clenbuterol increased combined hindlimb muscle weight 19% and 28% in young rats, with 19% and 25% increases in old rats. Similarly, these drugs increased gastrocnemius weight and protein content 19% and 24% in young rats, with 19% and 23% increases in old rats. Salbutamol and clenbuterol increased carcass protein content 20% and 30% in young rats, with 12% and 21% increases in old rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- W J Carter
- Veterans Administration Medical Center, Little Rock, AR
| | | |
Collapse
|
29
|
Carter WJ, Lynch ME. Effect of clenbuterol on recovery of muscle mass and carcass protein content following experimental hyperthyroidism in old rats. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. COMPARATIVE PHYSIOLOGY 1994; 108:387-94. [PMID: 7914859 DOI: 10.1016/0300-9629(94)90110-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The beta 2-adrenoceptor agonist, clenbuterol, has hastened the recovery of skeletal muscle and carcass weights and carcass protein stores lost during experimental hyperthyroidism in 24-month-old rats. Daily injection of 6.5 micrograms T3 per 100 g body weight for 2 weeks and 4.0 micrograms for the third week caused a 17-22% reduction in total body, carcass and combined hindlimb muscle weights, and a 16-21% reduction in carcass protein stores. Feeding diet containing 10 mg clenbuterol per kg during a 3-week recovery period caused complete restoration of these parameters to euthyroid control levels while the feeding control diet did not.
Collapse
Affiliation(s)
- W J Carter
- Veterans Administration Medical Center, Little Rock, AR 72205
| | | |
Collapse
|
30
|
Liu CC, Yeh JY, Ou BR, Forsberg NE. Actions of a beta-adrenergic agonist on muscle protein metabolism in intact, adrenalectomized, and dexamethasone-supplemented adrenalectomized rats. J Nutr Biochem 1994. [DOI: 10.1016/0955-2863(94)90008-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Maltin CA, Delday MI. Satellite cells in innervated and denervated muscles treated with clenbuterol. Muscle Nerve 1992; 15:919-25. [PMID: 1495507 DOI: 10.1002/mus.880150809] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The sympathomimetic agent, clenbuterol, induces a muscle-specific hypertrophy in both normal and catabolic muscle. Drug-induced hypertrophy is not generally associated with an increase in DNA content, thus the role of satellite cells in the response of soleus muscles from weanling rats is questioned. Following simultaneous sciatic section and administration of clenbuterol, responses are similar in innervated and denervated muscles after 4 days. Increased protein accretion in treated muscles is associated with evidence of satellite cell activation, but with little evidence of division. It is speculated that satellite cell production of growth factors may play an important role in the hypertrophic action of clenbuterol, and the clinical implications of the findings are discussed.
Collapse
Affiliation(s)
- C A Maltin
- Rowett Research Institute, Bucksburn, Aberdeen, United Kingdom
| | | |
Collapse
|
32
|
Brown J, Clasper C, Smith T, Lomax MA. Effects of a β2-adrenergic agonist, cimaterol and corticosterone on growth and carcass composition of male rats. ACTA ACUST UNITED AC 1992; 102:217-20. [PMID: 1351819 DOI: 10.1016/0300-9629(92)90037-q] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
1. Growth rate and carcass composition were measured in rats treated with cimaterol or vehicle only for 21 days, with corticosterone administered during the last 7 days of cimaterol or vehicle only treatment. 2. Cimaterol significantly stimulated the amount of protein in the carcass as well as gastrocnemius and plantaris muscles by 9-15%, and decreased carcass fat by 24%. 3. Corticosterone treatment significantly decreased protein in the carcass and soleus, plantaris and gastrocnemius muscles by 13-33%. 4. The catabolic effects of corticosterone on carcass and muscle protein were reduced by pretreatment with cimaterol, suggesting that beta-adrenergic agonists may have some potential use in preventing muscle wasting during stressed states.
Collapse
Affiliation(s)
- J Brown
- School of Animal and Microbial Sciences, University of Reading, Berkshire, U.K
| | | | | | | |
Collapse
|
33
|
Mantle D, Delday MI, Maltin CA. Effect of clenbuterol on protease activities and protein levels in rat muscle. Muscle Nerve 1992; 15:471-8. [PMID: 1565115 DOI: 10.1002/mus.880150410] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
To elucidate the biochemical mechanism by which the sympathomimetic agent clenbuterol promotes skeletal muscle growth, we have determined the activity of a range of proteolytic enzyme types (acid, neutral and alkaline proteinases and peptidases), together with the levels of soluble and structural proteins (via SDS-polyacrylamide gel electrophoresis) in 5 innervated and denervated muscle types from control and drug-treated rats. No gross change in activity was found for any enzyme type in any muscle (innervated or denervated) following clenbuterol treatment; however, one enzyme, arginyl aminopeptidase, showed a small but consistent decrease in activity in all of the innervated muscles investigated. Similar fractionation profiles were obtained for structural or soluble proteins from corresponding muscle types (innervated or denervated) in control or clenbuterol-treated animals, with the exception of cardiac muscle, which showed a 50% increase in staining intensity of one band (subunit molecular mass 18 kD). We conclude that the anabolic action of clenbuterol in promoting skeletal muscle growth does not occur via downregulation of protease activity, or increase in levels of individual muscle proteins.
Collapse
Affiliation(s)
- D Mantle
- Neurochemistry Department, Regional Neurological Centre, Newcastle General Hospital, Newcastle upon Tyne, UK
| | | | | |
Collapse
|
34
|
Abstract
Chronic administration of some beta-adrenergic agonists markedly stimulates hypertrophy of skeletal muscles. It appears that type II fibers are more responsive to beta-adrenergic agonists than type I fibers. The hypertrophic effect of beta-adrenergic agonists is transient, with the effect diminishing during prolonged treatment. Similarly, some cellular responses including the increase in RNA concentration and the decrease in calpain I activity are also short-lived. Recent evidence suggests that the temporal response is associated with decreased beta-adrenoceptor density. Both increased rate of protein synthesis and/or decreased protein degradation have been suggested as the mechanism of action of these compounds on hypertrophy of skeletal muscles. It is important to consider the temporal nature of cellular responses to chronic treatment of beta-adrenergic agonists as well as the differential effects of these compounds on protein metabolism among skeletal muscle fiber types when investigating the mechanism(s) of action of these compounds.
Collapse
Affiliation(s)
- Y S Kim
- University of Hawaii, Manoa 96822
| | | |
Collapse
|
35
|
Maltin CA, Delday MI, Hay SM, Baillie AG. Denervation increases clenbuterol sensitivity in muscle from young rats. Muscle Nerve 1992; 15:188-92. [PMID: 1549139 DOI: 10.1002/mus.880150210] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Clenbuterol has been shown to ameliorate denervation-induced atrophy and, therefore, clearly has therapeutic potential in the treatment of muscle wasting conditions in man. Previous studies have used dosages in rats which would be unacceptable in clinical practice, but the present results show that denervated muscle has a greater sensitivity to the drug than innervated or cardiac muscle. Fiber hypertrophy and an increase in protein and RNA content could be observed in denervated muscles but not in innervated muscles at a dose of 10 micrograms/kg body weight. When considered on a metabolic body weight basis, the effective dose in rats and the "safe" dose in man are surprisingly comparable. The observations imply that there is good reason to suppose that clenbuterol could be effective in ameliorating similar wasting conditions in man.
Collapse
Affiliation(s)
- C A Maltin
- Rowett Research Institute, Bucksburn, Aberdeen, UK
| | | | | | | |
Collapse
|
36
|
Carter WJ, Dang AQ, Faas FH, Lynch ME. Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats. Metabolism 1991; 40:855-60. [PMID: 1861634 DOI: 10.1016/0026-0495(91)90015-o] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Aging decreases skeletal muscle mass and strength, which may be exacerbated by age-related diseases. There is a need for therapeutic agents to prevent or restore loss of skeletal muscle in elderly subjects with muscle wasting disorders. Clenbuterol, a beta 2-adrenergic agonist, dramatically increases skeletal muscle mass in young animals and partially prevents or restores muscle loss in experimental models of muscle wasting. However, the protein anabolic and fat catabolic effects of clenbuterol have not been studied in senescent animals. To determine whether this drug has potential for preventing or repairing muscle loss in elderly subjects, we have examined its effects in young and old rats. Clenbuterol was administered by implanted osmotic minipumps to Fischer-344 rats ages 3, 12, and 23 months, at a dose of 1.5 mg/kg/24 h for 3 weeks. The weights of five hindlimb muscles and carcass protein and fat content were determined. Clenbuterol treatment increased the weight of skeletal muscles 22% to 39% in 3-month-old rats, 19% to 35% in 12-month-old rats, and 22% to 25% in 23-month-old animals. Likewise, clenbuterol increased carcass protein content 19% in 3-month-old rats, 16% in 12-month-old rats, and 24% in 23-month-old animals. Conversely, the drug reduced carcass fat content 36% in 3-month-old rats, 32% in 12-month-old rats, and 38% in 23-month-old rats. Therefore, clenbuterol had similar anabolic and catabolic effects in all age groups. In addition, clenbuterol stimulated recovery of skeletal muscle protein lost following pump implantation in senescent rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- W J Carter
- Veterans Administration Medical Center, Little Rock, AR
| | | | | | | |
Collapse
|
37
|
Benson DW, Foley-Nelson T, Chance WT, Zhang FS, James JH, Fischer JE. Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 1991; 50:1-5. [PMID: 1670961 DOI: 10.1016/0022-4804(91)90002-4] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Daily treatment of Fischer-344 rats for 14 days with the beta 2-adrenergic agonist, clenbuterol, increased gastrocnemius muscle mass and protein content. Coadministration with the beta-adrenergic antagonist, nadolol, significantly reduced these anabolic effects of clenbuterol. Although clenbuterol treatment reduced food intake during the first 4 days, clenbuterol-treated rats were hyperphagic during the second week of drug administration. Nadolol treatment also blocked these effects of clenbuterol on feeding. In a second experiment, in vitro incubation of extensor digitorum longus muscles taken from post weaning food-deprived rats demonstrated decreased release of 3-methylhistidine by clenbuterol-treated rats, suggesting decreased breakdown of myofibrillar protein. Protein synthesis was not increased in vitro in the soleus muscles taken from these rats. These experiments demonstrate that the anabolic effect of clenbuterol is due in part to beta-adrenergic activity and may involve reduced myofibrillar protein degradation. These results appear to have direct application to nutrition and protein repletion in various catabolic diseases.
Collapse
Affiliation(s)
- D W Benson
- Department of Surgery, University of Cincinnati Medical Center, Ohio 45267
| | | | | | | | | | | |
Collapse
|
38
|
|
39
|
Schauer JE, Schelin A, Hanson P, Stratman FW. Dehydroepiandrosterone and a beta-agonist, energy transducers, alter antioxidant enzyme systems: influence of chronic training and acute exercise in rats. Arch Biochem Biophys 1990; 283:503-11. [PMID: 1980404 DOI: 10.1016/0003-9861(90)90674-n] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
We examined the influence of dehydroepiandrosterone (DHEA), a beta-agonist, and exercise training on enzymes that detoxify toxic oxygen species. Feeding 0.4% DHEA decreased hepatic cytosolic (c) selenium-dependent glutathione peroxidase (GPX), (-26%, P less than 0.0001) and increased hepatic mitochondrial (m) Mn superoxide dismutase (SOD), (+38%, P less than 0.001). DHEA decreased myocardial c-GPX (-21%, P less than 0.05) when compared to a beta-agonist (beta A; L644969 Merck and Co.) fed at 5 ppm but neither differed from the Control (C). In contrast, the beta A increased hepatic m-GPX (+25%, P less than 0.05). In skeletal muscle, DHEA and beta A decreased muscle c-GPX by 20 and 12%, respectively (P less than 0.0009). DHEA increased both muscle (+20%, P less than 0.01) and myocardial (+20%, P less than 0.05) c-glutathione S-transferase (GST) over beta A (+20%, P less than 0.01) but neither was significantly different from C. Similar to DHEA, chronic training (Tr) (1 h/day, 5 days/week at 27 m/min, 15% grade on treadmill) decreased hepatic c-GPX (-16%, P less than 0.003). Tr elevates muscle c-GPX (+36%, P less than 0.05) in C. Tr increased myocardial c-GPX by 28% in the beta A-treated rats, whereas Tr decreased myocardial c-GPX by 22% in the C (P less than 0.05, interaction). One hour of acute exercise (Ex) (70% VO2 max relative work load) decreased hepatic homogenate catalase (-12%, P less than 0.02) and increased hepatic m-Mn SOD (+28%, P less than 0.03). Ex decreased myocardial c-GST (P less than 0.05) only in the DHEA-treated rats. DHEA and Tr may improve efficiency of oxygen utilization at the tissue level with lower antioxidant enzyme activity in liver and locally protective up-regulation in muscle. beta A stresses oxygen utilization systems and liver responds by up-regulation of antioxidant enzymes. The increase in myocardial c-GPX activity in the beta A-treated group may be a protective effect against indirect catecholamine-induced myocardial necrosis which results from free radical generation.
Collapse
Affiliation(s)
- J E Schauer
- Institute for Enzyme Research, University of Wisconsin, Madison 53705
| | | | | | | |
Collapse
|
40
|
Choo JJ, Horan MA, Little RA, Rothwell NJ. Effects of the beta 2-adrenoceptor agonist, clenbuterol, on muscle atrophy due to food deprivation in the rat. Metabolism 1990; 39:647-50. [PMID: 1693748 DOI: 10.1016/0026-0495(90)90034-a] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effects of a beta 2-adrenoceptor agonist, clenbuterol, on body weight and protein metabolism of gastrocnemius muscle, heart, and liver were studied in rats subjected to 50% food restriction or fasting. Food restriction by 50% for 7 days caused a complete cessation of growth and reductions in the mass, protein, and RNA content of muscle, heart, and liver. The ratio of RNA to protein content was also suppressed in muscle and heart, but not in liver. Fasting for 3 days caused loss of body weight (BW), reductions in the mass, protein, and RNA content, and the ratio of RNA to protein of gastrocnemius muscle, heart, and liver. Oral administration of clenbuterol (approximately 0.6 mg/kg BW/d) to food-restricted animals did not affect BW, but did increase in the mass, protein, and RNA content, and the ratio of RNA to protein of gastrocnemius muscle. The protein content of heart was also increased. Twice-daily injections of clenbuterol (2 mg/kg body weight/d) to fasting animals had no effect on BW or the mass or protein content of gastrocnemius muscle or liver, but both parameters were stimulated in heart. The results indicate that the anabolic action of clenbuterol are maintained when substrate availability is reduced by food restriction, but this effect is lost during severe protein and energy deficit (fasting).
Collapse
Affiliation(s)
- J J Choo
- Department of Physiological Sciences, University of Manchester Medical School, UK
| | | | | | | |
Collapse
|
41
|
Agbenyega ET, Wareham AC. Effect of clenbuterol on normal and denervated muscle growth and contractility. Muscle Nerve 1990; 13:199-203. [PMID: 2320041 DOI: 10.1002/mus.880130305] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The reported anabolic action of some beta 2 agonists may have clinical applications in certain muscle wasting states. Administration of clenbuterol (2 mg/kg diet for 14 days) to rats resulted in a limited degree of hypertrophy of normal muscles; the effect was more pronounced on fast-twitch muscles than on slow-twitch muscles. The anabolic effect was greatest in denervated muscles, where it was significantly more effective on the slow-twitch type. Clenbuterol significantly improved the contractile properties of denervated slow-twitch muscle, reverting them toward normal, but had little effect on contractile properties of denervated fast-twitch muscle. Such differential effects of clenbuterol must be taken into consideration in the evaluation of any future human intervention study.
Collapse
Affiliation(s)
- E T Agbenyega
- Department of Physiological Sciences, School of Biological Sciences, Medical School, University of Manchester, United Kingdom
| | | |
Collapse
|
42
|
Inkster JE, Hovell FD, Kyle DJ, Brown DS, Lobley GE. The effect of clenbuterol on basal protein turnover and endogenous nitrogen loss of sheep. Br J Nutr 1989; 62:285-96. [PMID: 2819013 DOI: 10.1079/bjn19890030] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Seven measurements of the effect of clenbuterol on basal nitrogen excretion (UNE), and protein turnover were made in six female sheep. The sheep were sustained by the intraruminal infusion of energy as volatile fatty acids to provide maintenance, but given no protein (N-free) for 12 d (6 d control, 6 d clenbuterol). Clenbuterol reduced UNE by 20%, but only on day 2 of the 6 d subperiod. Protein flux (equivalent to degradation on N-free nutrition), measured on day 6 by the irreversible loss of leucine was significantly increased (12%) by clenbuterol. Amino-N oxidation measured by N excretion was unchanged and, therefore, protein synthesis was also increased. During the 12 d N-free period, the recovery of urinary total N (Kjeldahl) as the sum of urea, ammonia, creatinine and purine derivatives, declined from 87.7 to 74.2%. The form of this missing N was not identified. The effect of clenbuterol of increasing both degradation and synthesis is unlike that reported in the literature for animals receiving protein when, in general, synthesis is unchanged and degradation reduced. This could be due to a different effect of clenbuterol in the N-free state, or to unchanged effects on protein pools other than muscle whose relative contribution to protein metabolism is different in the N-free state.
Collapse
Affiliation(s)
- J E Inkster
- Rowett Research Institute, Bucksburn, Aberdeen
| | | | | | | | | |
Collapse
|
43
|
Maltin CA, Hay SM, Delday MI, Lobley GE, Reeds PJ. The action of the beta-agonist clenbuterol on protein metabolism in innervated and denervated phasic muscles. Biochem J 1989; 261:965-71. [PMID: 2803256 PMCID: PMC1138923 DOI: 10.1042/bj2610965] [Citation(s) in RCA: 67] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
1. Clenbuterol treatment in innervated and denervated phasic extensor digitorum longus, plantaris and gastrocnemius muscles from rats caused a significant increase in RNA and protein contents in all muscles except denervated extensor digitorum longus. 2. All muscles showed an increase in the fractional rate of protein synthesis (Ks) with clenbuterol, but the temporal response varied. 3. The data suggest that the effect of clenbuterol on protein metabolism in innervated muscles is muscle-type specific, and demonstrate the homology of response for denervated muscles.
Collapse
Affiliation(s)
- C A Maltin
- Rowett Research Institute, Bucksburn, Aberdeen, U.K
| | | | | | | | | |
Collapse
|
44
|
Maltin CA, Hay SM, Delday MI, Reeds PJ, Palmer RM. Evidence that the hypertrophic action of clenbuterol on denervated rat muscle is not propranolol-sensitive. Br J Pharmacol 1989; 96:817-22. [PMID: 2472845 PMCID: PMC1854445 DOI: 10.1111/j.1476-5381.1989.tb11889.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
1. The effect of propranolol on the clenbuterol-induced protein anabolism in innervated and denervated soleus and plantaris muscles of the rat was studied. 2. The response to the beta-agonist, clenbuterol, in both innervated and denervated muscles, was not significantly inhibited by the beta-antagonist, propranolol. 3. The results provide further evidence to suggest that the action of clenbuterol on skeletal muscle protein accretion may not be directly mediated by beta-adrenoceptors.
Collapse
Affiliation(s)
- C A Maltin
- Rowett Research Institute, Bucksburn, Aberdeen
| | | | | | | | | |
Collapse
|
45
|
Garlick PJ, Burns HJ, Palmer RM. Regulation of muscle protein turnover: possible implications for modifying the responses to trauma and nutrient intake. BAILLIERE'S CLINICAL GASTROENTEROLOGY 1988; 2:915-40. [PMID: 3149908 DOI: 10.1016/0950-3528(88)90042-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The physiological control of muscle protein balance has been reviewed. In addition to trauma, fasting and reduced activity have been shown to cause muscle protein loss through changes in synthesis and breakdown. Many of the effects of these states are mediated by alterations in the concentrations of insulin, glucagon, steroids and catecholamines. Branched-chain amino acids also appear to have specific effects in improving protein synthesis. Recently, prostaglandins have been identified as having a central role as mediators in the control of protein metabolism by many hormones and pathological states. Identification of factors which control muscle protein synthesis leads to the possibility that the metabolic response to illness and injury and its attendant muscle protein loss could be open to pharmacological manipulation. Inhibition of prostaglandin synthesis by non-steroidal anti-inflammatory drugs can improve muscle protein turnover, but their clinical usefulness may be limited by side-effects. Hormonal manipulation may offer the possibility of abolishing the metabolic response. For example, inhibition of adrenal secretion in surgical patients by spinal anaesthesia appears to modify many of the metabolic effects of injury. A variety of other treatments have been used to minimize the metabolic derangements of injury. Some of these have considerable potential, but as yet clinical benefits from their use have not been positively identified. It is likely that a pharmacological approach to the nutritional disorders of stress and injury will prove to be of major interest in the future.
Collapse
|
46
|
Rothwell NJ, Stock MJ. Increased body-weight gain and body protein in castrated and adrenalectomized rats treated with clenbuterol. Br J Nutr 1988; 60:355-60. [PMID: 3196675 DOI: 10.1079/bjn19880105] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
1. Daily injection of the beta 2-adrenergic agonist clenbuterol (1 mg/kg body-weight) increased weight gain by 12% in young (35 d) male rats and by 18% in castrated rats, but had no effect on energy intake, expenditure or efficiency in either group. 2. Body fat content was not affected by clenbuterol or castration, but water and protein content were significantly increased by clenbuterol treatment in both intact and castrated rats. The ratio, body protein: fat was increased by 13 and 16% in these two groups compared with their respective, untreated controls. 3. Bilateral surgical adrenalectomy (ADX) of young (45 d) male rats significantly reduced body-weight, and energy intake, expenditure and efficiency. Carcass energy and fat contents were also reduced in ADX rats compared with age-matched controls. 4. Clenbuterol injections stimulated weight gain (% increase:intact 15, ADX 35), and increased body protein content (% increase:intact 12, ADX 8) and the ratio, carcass protein:fat (% increase:intact 34, ADX 23). 5. These findings demonstrate that the effects of clenbuterol on body-weight gain and composition in male rats occur in the absence of either gonadal or adrenal hormones. Together with other studies, these results provide further evidence to suggest that clenbuterol probably exerts its effects by a direct action on lean body mass.
Collapse
Affiliation(s)
- N J Rothwell
- Department of Physiology, St George's Hospital Medical School, Tooting, London
| | | |
Collapse
|
47
|
Maltin CA, Hay SM, Delday MI, Smith FG, Lobley GE, Reeds PJ. Clenbuterol, a beta agonist, induces growth in innervated and denervated rat soleus muscle via apparently different mechanisms. Biosci Rep 1987; 7:525-32. [PMID: 2447978 DOI: 10.1007/bf01116510] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Dietary administration of the anabolic agent, clenbuterol, has already been shown to inhibit or reverse denervation-induced atrophy in rat soleus muscles. We now show that the ameliorative effects of clenbuterol in denervated rat muscles are due principally to a large increase in protein synthesis. This results from both an increase in protein synthetic capacity and a normalised translational efficiency. The responses of innervated and denervated muscles are therefore fundamentally different, the changes in denervated muscles being reminiscent of the classical pleiotypic response of cells to growth factors.
Collapse
Affiliation(s)
- C A Maltin
- Rowett Research Institute, Bucksburn, Aberdeen
| | | | | | | | | | | |
Collapse
|
48
|
Maltin CA, Delday MI, Hay SM, Smith FG, Lobley GE, Reeds PJ. The effect of the anabolic agent, clenbuterol, on overloaded rat skeletal muscle. Biosci Rep 1987; 7:143-9. [PMID: 2443196 DOI: 10.1007/bf01121878] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The dietary administration of clenbuterol to young male rats has been shown to produce a muscle specific hypertrophic growth response. This paper demonstrates that the combined effect of drug treatment and hypertrophic stimulus induced by tenotomy produced an additive effect on muscle growth. This effect was demonstrated in terms of both muscle composition (protein and RNA) and fibre size.
Collapse
Affiliation(s)
- C A Maltin
- Rowett Research Institute, Bucksburn, Aberdeen
| | | | | | | | | | | |
Collapse
|
49
|
Maltin CA, Delday MI, Hay SM, Smith FG, Reeds PJ. Propranolol apparently separates the physical and compositional characteristics of muscle growth induced by clenbuterol. Biosci Rep 1987; 7:51-7. [PMID: 2441771 DOI: 10.1007/bf01122727] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The effect of propranolol on clenbuterol-induced changes in muscle fibre size and protein content were studied. Propranolol did not inhibit the ability of clenbuterol to stimulate protein accretion but reduced the increase in muscle fibre size. The compositional and physical characteristics of clenbuterol-induced muscle growth thus appeared to be separated by propranolol.
Collapse
|